International Journal of Nephrology [33] Y. Imanishi, M. Inaba, K. Nakatsuka et al., “FGF-23 in patients with end-stage renal disease on hemodialysis,” Kidney Interna- tional, vol. 65, no. 5, pp. 1943–1946, 2004. [34] N. Koh, T. Fujimori, S. Nishiguchi et al., “Severely reduced production of klotho in human chronic renal failure kidney,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1015–1020, 2001. [35] O. M. Gutie´rrez, M. Mannstadt, T. Isakova et al., “Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 359, no. 6, pp. 584–592, 2008. [36] M. A. I. Mirza, A. Larsson, L. Lind, and T. E. Larsson, “Circulating ﬁbroblast growth factor-23 is associated with vascular dysfunction in the community,” Atherosclerosis, vol. 205, no. 2, pp. 385–390, 2009. [37] M. A. I. Mirza, T. Hansen, L. Johansson et al., “Relationship between circulating FGF23 and total body atherosclerosis in the community,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3125–3131, 2009. [38] G. Jean, J. C. Terrat, T. Vanel et al., “High levels of serum ﬁbroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients,” Nephrol- ogy Dialysis Transplantation, vol. 24, no. 9, pp. 2792–2796, 2009. [39] M. Inaba, S. Okuno, Y. Imanishi et al., “Role of ﬁbroblast growth factor-23 in peripheral vascular calciﬁcation in non- diabetic and diabetic hemodialysis patients,” Osteoporosis International, vol. 17, no. 10, pp. 1506–1513, 2006. [40] O. M. Gutie´rrez, J. L. Januzzi, T. Isakova et al., “Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease,” Circulation, vol. 119, no. 19, pp. 2545–2552, 2009. [41] G. Jean, E. Bresson, J. C. Terrat et al., “Peripheral vascular calciﬁcation in long-haemodialysis patients: associated factors and survival consequences,” Nephrology Dialysis Transplanta- tion, vol. 24, no. 3, pp. 948–955, 2009. [42] Q. W. Pan, R. X. Ruan, D. A. Wheeler et al., “Fibroblast growth factor-23 inhibits inﬂammation-induced calciﬁcation in vitro in human vascular smooth muscle cells,” ASN Renal Week, 2009. [43] F. Saji, K. Shiizaki, S. Shimada et al., “Regulation of ﬁbroblast growth factor 23 production in bone in uremic rats,” Nephron. Physiology, vol. 111, no. 4, pp. 59–66, 2009. [44] O. Gutierrez, T. Isakova, E. Rhee et al., “Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates cal- citriol deﬁciency in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2205–2215, 2005. [45] S. Pande, C. S. Ritter, M. Rothstein et al., “FGF-23 and sFRP- 4 in chronic kidney disease and post-renal transplantation,” Nephron—Physiology, vol. 104, no. 1, pp. p23–p32, 2006. [46] G. A. Block, T. E. Hulbert-Shearon, N. W. Levin, and F. K. Port, “Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 607–617, 1998. [47] G. A. Block, P. S. Klassen, J. M. Lazarus, N. Ofsthun, E. G. Lowrie, and G. M. Chertow, “Mineral metabolism, mortality, and morbidity in maintenance hemodialysis,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2208–2218, 2004. [48] K. Kalantar-Zadeh, N. Kuwae, D. L. Regidor et al., “Survival predictability of time-varying indicators of bone disease in 5 maintenance hemodialysis patients,” Kidney International, vol. 70, no. 4, pp. 771–780, 2006. [49] M. L. Melamed, J. A. Eustace, L. Plantinga et al., “Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study,” Kidney International, vol. 70, no. 2, pp. 351–357, 2006. [50] M. Noordzij, J. C. Korevaar, E. W. Boeschoten, F. W. Dekker, W. J. Bos, and R. T. Krediet, “The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients,” American Journal of Kidney Diseases, vol. 46, no. 5, pp. 925–932, 2005. [51] Y. Slinin, R. N. Foley, and A. J. Collins, “Calcium, phos- phorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1788–1793, 2005. [52] L. A. Stevens, O. Djurdjev, S. Cardew, E. C. Cameron, and A. Levin, “Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 770–779, 2004. [53] P. Ravani, F. Malberti, G. Tripepi et al., “Vitamin D levels and patient outcome in chronic kidney disease,” Kidney International, vol. 75, no. 1, pp. 88–95, 2009. [54] R. Shroﬀ, M. Egerton, M. Bridel et al., “A bimodal association of vitamin d levels and vascular disease in children on dialysis,” Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1239–1246, 2008. [55] M. Wolf, A. Shah, O. Gutierrez et al., “Vitamin D levels and early mortality among incident hemodialysis patients,” Kidney International, vol. 72, no. 8, pp. 1004–1013, 2007. [56] D. Medici, M. S. Razzaque, S. DeLuca et al., “FGF-23—Klotho signaling stimulates proliferation and prevents vitamin D- induced apoptosis,” Journal of Cell Biology, vol. 182, no. 3, pp. 459–465, 2008. [57] M. S. Razzaque, “Does FGF23 toxicity inﬂuence the outcome of chronic kidney disease?” Nephrology Dialysis Transplanta- tion, vol. 24, no. 1, pp. 4–7, 2009.